Suppr超能文献

氟伐他汀与口服降糖药在健康受试者及非胰岛素依赖型糖尿病患者中无相互作用。

Lack of interaction between fluvastatin and oral hypoglycemic agents in healthy subjects and in patients with non-insulin-dependent diabetes mellitus.

作者信息

Appel S, Rüfenacht T, Kalafsky G, Tetzloff W, Kallay Z, Hitzenberger G, Kutz K

机构信息

Department of Clinical Pharmacology, Sandoz Pharma, Basel, Switzerland.

出版信息

Am J Cardiol. 1995 Jul 13;76(2):29A-32A. doi: 10.1016/s0002-9149(05)80012-8.

Abstract

Human drug interaction studies in vivo are conducted when in vitro and/or animal interactions suggest clinical relevance. Studies in vitro have indicated that the new, entirely synthetic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin affects the metabolism of the nonsteroidal anti-inflammatory drug diclofenac and the oral hypoglycemic tolbutamide. Diclofenac and tolbutamide are both model substrates of the CYP2C isozymes, suggesting that this enzyme could be involved in the underlying mechanism of interaction. The concomitant use of lipid-lowering drugs with oral hypoglycemic agents has been recommended in patients with non-insulin-dependent diabetes mellitus (NIDDM). Therefore, 2 studies were initiated to explore potential pharmacokinetic and pharmacodynamic interactions between fluvastatin, simvastatin, or placebo and the oral hypoglycemic agents tolbutamide (study I) and glyburide (study II), each in 16 healthy subjects. These compounds were selected because of a demonstrated in vitro interaction with tolbutamide and widespread clinical use of glyburide. A further study (study III) was conducted to investigate the potential pharmacokinetic and pharmacodynamic interactions between fluvastatin and glyburide under therapeutic conditions in 32 patients with NIDDM. Single and multiple coadministration of fluvastatin 40 mg or simvastatin 20 mg increased the mean maximum plasma concentration and area under the concentration-time curve of glyburide by about 20%. The pharmacokinetics of tolbutamide were influenced to only a minor extent. Fluvastatin concentration-time profiles were unaffected by tolbutamide or glyburide coadministration. However, the pharmacokinetic interactions between fluvastatin or simvastatin and tolbutamide and glyburide were not associated with clinically relevant changes in blood glucose and insulin concentrations and, therefore, are not considered to be relevant in therapeutic practice.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

当体外和/或动物实验显示有临床相关性时,会进行人体药物相互作用的体内研究。体外研究表明,全新的全合成3-羟基-3-甲基戊二酰辅酶A还原酶抑制剂氟伐他汀会影响非甾体抗炎药双氯芬酸和口服降糖药甲苯磺丁脲的代谢。双氯芬酸和甲苯磺丁脲都是CYP2C同工酶的典型底物,这表明该酶可能参与了相互作用的潜在机制。对于非胰岛素依赖型糖尿病(NIDDM)患者,建议同时使用降脂药物和口服降糖药。因此,开展了两项研究,以探索氟伐他汀、辛伐他汀或安慰剂与口服降糖药甲苯磺丁脲(研究I)和格列本脲(研究II)之间潜在的药代动力学和药效学相互作用,每项研究纳入16名健康受试者。选择这些化合物是因为它们在体外与甲苯磺丁脲有相互作用,且格列本脲临床应用广泛。还进行了另一项研究(研究III),以调查在治疗条件下32名NIDDM患者中氟伐他汀与格列本脲之间潜在的药代动力学和药效学相互作用。单次和多次联合给予40mg氟伐他汀或20mg辛伐他汀可使格列本脲的平均最大血浆浓度和浓度-时间曲线下面积增加约20%。甲苯磺丁脲的药代动力学仅受到轻微影响。氟伐他汀的浓度-时间曲线不受甲苯磺丁脲或格列本脲联合给药的影响。然而,氟伐他汀或辛伐他汀与甲苯磺丁脲和格列本脲之间的药代动力学相互作用与血糖和胰岛素浓度的临床相关变化无关,因此在治疗实践中不被认为具有相关性。(摘要截选至250词)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验